|
Age, yearsa, †
|
55.1 ± 11.1
|
63.1 ± 10.6
|
<0.001*
|
|
Male sexb
|
168 (77.4)
|
25 (75.8)
|
0.832
|
|
Diabetes mellitusb
|
36 (16.6)
|
12 (36.4)
|
0.007*
|
|
Hypertensionb
|
60 (27.6)
|
16 (48.5)
|
0.015*
|
|
Coexisting cirrhosisb
|
126 (58.1)
|
21 (63.6)
|
0.545
|
|
Etiology of liver diseaseb
| | |
<0.001*
|
|
HBsAg (+)
|
167 (77.0)
|
16( 48.5)
| |
|
Anti-HCV (+)
|
19 (8.8)
|
2 (6.1)
|
|
Alcohol
|
9 (4.1)
|
6 (18.8)
|
|
Other
|
22 (10.1)
|
9 (27.30)
|
|
CTP scoreb
| | |
1.000
|
|
A
|
206 (94.9)
|
32 (97.0)
| |
|
B
|
11 (5.1)
|
1 (3.0)
|
|
MELD scorea
|
6.1 ± 3.4
|
5.4 ± 3.3
|
0.210
|
|
AST (IU/L)a
|
54.9 ± 74.1
|
33.6 ± 13.8
|
0.024*
|
|
ALT (IU/L)a
|
55.8 ± 90.1
|
31.3 ± 17.4
|
0.016*
|
|
Total bilirubin (mg/dL)a
|
1.5 ± 7.1
|
0.7 ± 0.3
|
0.020*
|
|
Serum albumin (g/dL)a
|
4.0 ± 0.5
|
3.9 ± 0.5
|
0.126
|
|
Platelet count (×103/μL)a
|
162.7 ± 72.7
|
171.2 ± 65.6
|
0.439
|
|
APRI scorea
|
1.1 ± 1.4
|
0.6 ± 0.3
|
0.034*
|
|
AFP (ng/mL)b
| | |
0.149
|
|
<20
|
109 (50.9)
|
20 (64.5)
| |
|
20–200
|
41 (19.2)
|
5 (16.1)
|
|
>200b
|
64 (29.9)
|
6 (19.4)
|
|
pTNM stage of HCCb
| | |
0.259
|
|
I
|
106 (40.8)
|
19 (57.6)
| |
|
II
|
77 (35.5)
|
11 (33.3)
|
|
III or IV
|
34 (15.7)
|
3(9.1)
|
|
Portal vein or major vessel invasionb
|
11 (5.1)
|
3 (9.1)
|
0.406
|
|
Microvessel invasionb
|
86 (39.6)
|
12 (36.4)
|
0.720
|
|
Tumor sizea
|
4.2 ± 2.8
|
3.8 ± 2.5
|
0.477
|
|
Follow-up duration (months)a
|
48.5 ± 26.2
|
36.0 ± 30.0
|
0.013*
|
|
Overall median survival (months)
|
46.0
|
27.0
|
0.178
|
|
HCC recurrenceb
|
114 (52.5)
|
10 (30.3)
|
0.017*
|
|
Time to recurrence (months)a
|
17.8 ± 16.8
|
21.4 ± 17.5
|
0.548
|
|
Number of deathsb
|
54 (24.9)
|
11 (33.3)
|
0.303
|
|
Time to death (months)a
|
29.8 ± 22.6
|
15.2 ± 15.3
|
0.045*
|
|
Cause of deathb
| | |
0.005*
|
|
Liver-related
|
50 (92.6)
|
6 (54.5)
| |
|
Other
|
4 (7.4)
|
5 (45.5)
|
